Switching from Cetrorelix to Dydrogesterone in an IVF Cycle - a New Strategy for Unexpected Freeze-all Cycles

Overview

Journal JBRA Assist Reprod

Specialty Reproductive Medicine

Date 2023 Oct 18

PMID 37850848

Authors

Roberto de Azevedo Antunes

Maria do Carmo Borges de Souza

Marcelo de Souza Marinho

Veronica de Almeida Raupp

Gabriela Palhano Sifuentes Melo

Affiliations

Soon will be listed here.

Abstract

Preventing a luteinizing hormone (LH) surge is a major concern in controlled ovarian stimulation (COS). Several strategies have been developed over the years, including protocols with Gonadotrophin Releasing Hormone agonists and antagonists. More recently Progestin Primmed Ovarian Stimulation (PPOS) has shown to be equally effective in pituitary suppression, with comparable clinical and laboratorial outcomes. This is the case of a 34 year old female, with a previous diagnosis of primary infertility due to tubal factor and high ovarian reserve markers. The initial plan was to perform IVF/ICSI. followed by fresh blastocyst transfer. The chosen COS strategy was to use Alfacorifolitropin 150mg (Elonva®) and Cetrorelix acetate 0,25mg (Cetrotide®) in a flexible pituitary suppression protocol. However, because of elevated risk for Ovarian Hyper-stimulation Syndrome (OHSS) detected during ultrasound and hormonal monitoring, in order to diminish financial burden and to have a more patient friendly protocol, we switched cetrorelix acetate to oral dydrogesterone. COS was successful and resulted in 24 retrieved oocytes (16 metaphase 2 oocytes) without any premature LH peak. No OHSS symptoms occurred. Our main goal with this case report is to reinforce the feasibility and efficacy of this innovative approach, especially in patients aiming for a fresh embryo transfer, who present alert sings of OHSS during the stimulation. Developing friendlier and cheaper protocols in assisted reproduction makes the treatment more accessible and affordable.

References

Evans M, Parikh T, DeCherney A, Csokmay J, Healy M, Hill M . Evaluation of the cost-effectiveness of ovulation suppression with progestins compared with GnRH analogs in assisted reproduction cycles. Reprod Biomed Online. 2019; 38(5):691-698. DOI: 10.1016/j.rbmo.2018.12.044. View

Yu S, Long H, Chang H, Liu Y, Gao H, Zhu J . New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod. 2018; 33(2):229-237. DOI: 10.1093/humrep/dex367. View

Kalafat E, Turkgeldi E, Yildiz S, Dizdar M, Keles I, Ata B . Outcomes of a GnRH Agonist Trigger Following a GnRH Antagonist or Flexible Progestin-Primed Ovarian Stimulation Cycle. Front Endocrinol (Lausanne). 2022; 13:837880. PMC: 9161281. DOI: 10.3389/fendo.2022.837880. View

Begueria R, Garcia D, Vassena R, Rodriguez A . Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Hum Reprod. 2019; 34(5):872-880. DOI: 10.1093/humrep/dez034. View

Huang J, Xie Q, Lin J, Lu X, Wang N, Gao H . Neonatal outcomes and congenital malformations in children born after dydrogesterone application in progestin-primed ovarian stimulation protocol for IVF: a retrospective cohort study. Drug Des Devel Ther. 2019; 13:2553-2563. PMC: 6667350. DOI: 10.2147/DDDT.S210228. View

Guan S, Feng Y, Huang Y, Huang J . Progestin-Primed Ovarian Stimulation Protocol for Patients in Assisted Reproductive Technology: A Meta-Analysis of Randomized Controlled Trials. Front Endocrinol (Lausanne). 2021; 12:702558. PMC: 8438422. DOI: 10.3389/fendo.2021.702558. View

Alexandru P, Guler Cekic S, Yildiz S, Turkgeldi E, Ata B . Progestins versus GnRH analogues for pituitary suppression during ovarian stimulation for assisted reproductive technology: a systematic review and meta-analysis. Reprod Biomed Online. 2020; 40(6):894-903. DOI: 10.1016/j.rbmo.2020.01.027. View

Ovarian Stimulation T, Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P . ESHRE guideline: ovarian stimulation for IVF/ICSI. Hum Reprod Open. 2020; 2020(2):hoaa009. PMC: 7203749. DOI: 10.1093/hropen/hoaa009. View

Wang L, Wang J, Zhang Y, Qian C, Wang X, Bai J . Analysis of euploidy rates in preimplantation genetic testing for aneuploidy cycles with progestin-primed versus GnRH agonist/antagonist protocol. Eur J Med Res. 2023; 28(1):28. PMC: 9841681. DOI: 10.1186/s40001-023-01000-1. View

10.

Zhu X, Zhang X, Fu Y . Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Medicine (Baltimore). 2015; 94(21):e909. PMC: 4616424. DOI: 10.1097/MD.0000000000000909. View

11.

La Marca A, Capuzzo M . Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era?. Reprod Biomed Online. 2019; 39(2):321-331. DOI: 10.1016/j.rbmo.2019.03.212. View

12.

Cui L, Lin Y, Wang F, Chen C . Effectiveness of progesterone-primed ovarian stimulation in assisted reproductive technology: a systematic review and meta-analysis. Arch Gynecol Obstet. 2021; 303(3):615-630. PMC: 7960625. DOI: 10.1007/s00404-020-05939-y. View

13.

Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q . Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015; 104(1):62-70.e3. DOI: 10.1016/j.fertnstert.2015.03.022. View

14.

Lambalk C, Banga F, Huirne J, Toftager M, Pinborg A, Homburg R . GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update. 2017; 23(5):560-579. DOI: 10.1093/humupd/dmx017. View

15.

Yildiz S, Turkgeldi E, Angun B, Eraslan A, Urman B, Ata B . Comparison of a novel flexible progestin primed ovarian stimulation protocol and the flexible gonadotropin-releasing hormone antagonist protocol for assisted reproductive technology. Fertil Steril. 2019; 112(4):677-683. DOI: 10.1016/j.fertnstert.2019.06.009. View

16.

Huang T, Lin Y, Pan S, Tu Y, Huang C, Chen M . A novel GnRH-antagonist protocol by switching to medroxyprogesterone when patients being at risk of ovarian hyperstimulation syndrome during ovarian stimulation. J Formos Med Assoc. 2020; 119(11):1642-1649. DOI: 10.1016/j.jfma.2019.12.006. View

17.

Eibschitz I, Frydman R . In vitro fertilization management and results in stimulated cycles with spontaneous luteinizing hormone discharge. Fertil Steril. 1986; 45(2):231-6. DOI: 10.1016/s0015-0282(16)49160-0. View

18.

Iwami N, Kawamata M, Ozawa N, Yamamoto T, Watanabe E, Moriwaka O . New trial of progestin-primed ovarian stimulation using dydrogesterone versus a typical GnRH antagonist regimen in assisted reproductive technology. Arch Gynecol Obstet. 2018; 298(3):663-671. DOI: 10.1007/s00404-018-4856-8. View